Abstract: The invention concerns a cassette for cell culture comprising: an at least partially rigid housing internally defining an internal space inside which a cell culture bag defining an internal volume is arranged and attached; conduits each connected at one end to the internal volume of the bag and each having a second end situated outside the housing; and valves for enabling/preventing the flow of fluid through the conduits that are mounted on the housing.

Abstract: The invention provides an automated apparatus of cell culture having tanks of culture medium, of growth factors and of cells to be cultured, an incubator having a thermostated enclosure which houses a cell culture vessel, and control computer system. A supporting and agitation device of the culture vessel is provided in the enclosure, and the culture vessel is formed by a bag having at least one inlet port connected to the tanks and one outlet port connected devices for harvesting and storage of the cells after culture, these harvesting and storage devices and tanks being located outside the enclosure and being connected to the cell expansion bag ports by conduits which together with the cell expansion bag form a preassembled module passing through a wall of the enclosure.

Abstract: The invention concerns a cassette (16) for cell culture comprising:—an at least partially rigid housing (90) internally defining an internal space inside which a cell culture bag (100) defining an internal volume is arranged and attached,—conduits (36, 38) each connected at one end to the internal volume of the bag (100) and each having a second end situated outside the housing (90),—valves (128, 130) for enabling/preventing the flow of fluid through the conduits (36, 38) that are mounted on the housing (90).

Abstract: The invention provides an automated apparatus of cell culture having tanks of culture medium, of growth factors and of cells to be cultured, an incubator having a thermostated enclosure which houses a cell culture vessel, and control computer system. A supporting and agitation device of the culture vessel is provided in the enclosure, and the culture vessel is formed by a bag having at least one inlet port connected to the tanks and one outlet port connected devices for harvesting and storage of the cells after culture, these harvesting and storage devices and tanks being located outside the enclosure and being connected to the cell expansion bag ports by conduits which together with the cell expansion bag form a preassembled module passing through a wall of the enclosure.

Abstract: A cellular cardiomyoplasty process based on the potential capacity of CD34+ cells to regenerate myocardium after acute myocardial infarct (AMI) and on their collection in blood in which the following phases are performed: Phase 1 a G-CSF-mobilization phase of CD-34+ cell is started as soon as the infarct is stabilized and its impact on heart function has been evaluated; Phase 2 a cell collecting phase is undertaken after G-CSF-mobilization; Phase 3 a cell processing phase is performed to select ex-vivo CD34+ cells and expand them in vitro to achieve around a 20-fold increase of the total number of CD34+ cells; Phase 4 a resuspension phase of the amplified-cell product in a final predetermined volume of autologous plasma, and Phase 5 a packaging phase of the cell suspension in a sterile syringue for reinjection to the patient.

Abstract: The invention concerns a cellular cardiomyoplasty process based on the potential capacity of CD34+ cells to regenerate myocardium after acute myocardial infarct (AMI) and on their collection in blood in which the following phases are performed: Phase 1 a G-CSF-mobilization phase of CD-34+ cell is started as soon as the infarct is stabilized and its impact on heart function has been evaluated. Phase 2 a cells collecting phase is undertaken after G-CSF-mobilization, Phase 3 a cells processing phase is performed to select ex-vivo CD34+ cells and expand them in vitro to achieve around a 20-fold increase of the total number of CD34+ cells. Phase 4 a resuspension phase of the amplified-cell product in a final predetermined volume of autologous plasma, and Phase 5 a packaging phase of the cell suspension in a sterile syringe for reinjection to the patient.